^
    Back
    Association details:
    Biomarker:RET rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

    Published date:
    07/11/2022
    Excerpt:
    For patients with a RET rearrangement, a PS of 0-2, and previously untreated NSCLC, clinicians may offer selpercatinib or pralsetinib. In second line, for patients with a RET rearrangement who have not received RET-targeted therapy, clinicians may offer selpercatinib or pralsetinib.
    DOI:
    10.1200/JCO.22.00824
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    The Panel recommends selpercatinib, pralsetinib, cabozantinib, or vandetanib (category 2B for vandetanib) as subsequent therapy options for select patients with RET rearrangement positive metastatic NSCLC who have not previously received these agents…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    Excerpt:
    ...- All participants (with the exception of participants with MTC enrolled in Groups 3, 4, and 9) must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or central testing of tumor or circulating tumor nucleic acid in blood; as detailed below....
    Trial ID:
    ARROW
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res Treat
    Title:

    Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

    Published date:
    05/22/2023
    Excerpt:
    This study evaluated the efficacy and safety of expanded access program (EAP) use of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement….ORR was 56.5%, the median PFS was 12.1 months (95% CI, 3.3-20.9), and the 12-month OS rate was 69.6%.... Pralsetinib presents a clinical benefit when used in patients with RET-rearranged NSCLC, consistent with a pivotal study.
    DOI:
    10.4143/crt.2023.403